The impact of p53 in predicting clinical outcome of breast cancer patients with visceral metastasis

In the study, we analyzed role of p53 in predicting outcome in visceral metastasis breast cancer (VMBC) patients. 97 consecutive VMBC patients were studied. P53 positivity rate was 29.9%. In the p53-negative group, median disease free survival (DFS), and time from primary breast cancer diagnosis to death (OS1), time from metastases to death (OS2) were 25, 42.5, and 13.5 months, respectively. In the p53-positive group, they were 10, 22, and 8 months, respectively. Statistically significant differences in DFS and OS1 were detected between the p53-negative and p53-positive subtypes. However, p53 appears to have no influence on OS2. In Cox regression analysis, p53 expression and TNM stage were predictive factors of DFS. In the multivariate analysis, p53 expression and the duration of DFS correlated with OS1, but not for OS2. Taken together, our data indicate p53 showing predicting role in OS1 for VMBC, but not for OS2.

[1]  A. Reiner,et al.  Coexpression of HER-2/neu and p53 is associated with a shorter disease-free survival in node-positive breast cancer patients , 2005, Journal of Cancer Research and Clinical Oncology.

[2]  M. Dai,et al.  Aberrant Expression of Nucleostemin Activates p53 and Induces Cell Cycle Arrest via Inhibition of MDM2 , 2008, Molecular and Cellular Biology.

[3]  Guy Leclercq,et al.  p53 and breast cancer, an update. , 2006, Endocrine-related cancer.

[4]  T. Toyama,et al.  p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer , 2006, Breast Cancer Research.

[5]  I. Ellis,et al.  The p53 positive Bcl‐2 negative phenotype is an independent marker of prognosis in breast cancer , 2007, International journal of cancer.

[6]  G. Striker,et al.  p53 protein and vimentin in invasive ductal NOS breast carcinoma--relationship with survival and sites of metastases. , 1994, European journal of cancer.

[7]  A. Børresen-Dale,et al.  TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes , 2007, Oncogene.

[8]  W. McCaskill-Stevens,et al.  p53 as a Marker of Prognosis in African-American Women with Breast Cancer , 2010, Annals of Surgical Oncology.

[9]  A. Janin,et al.  TP53 Status and Response to Treatment in Breast Cancers , 2011, Journal of biomedicine & biotechnology.

[10]  Liping Xie,et al.  Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells , 2013, World Journal of Surgical Oncology.

[11]  Jenny C. Chang,et al.  Survival of patients with metastatic breast carcinoma , 2003, Cancer.

[12]  A. Lazaris,et al.  PROGNOSTIC SIGNIFICANCE OF THE CO‐EXPRESSION OF p53 AND c‐erbB‐2 PROTEINS IN BREAST CANCER , 1996, The Journal of pathology.

[13]  M. Namer,et al.  Prognostic factors in 1,038 women with metastatic breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  J. Overgaard.  TP53 Mutation is an Independent Prognostic Marker for Poor Outcome in Both Node-negative and Node-positive Breast Cancer , 2000, Acta oncologica.

[15]  Annette Lee,et al.  P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency. , 2013, Critical reviews in oncology/hematology.

[16]  R. Elledge,et al.  p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. , 1994, Cancer research.

[17]  Varda Rotter,et al.  When mutants gain new powers: news from the mutant p53 field , 2009, Nature Reviews Cancer.

[18]  Sarkis Meterissian,et al.  Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer. , 2004, Journal of the American College of Surgeons.

[19]  D. Berry,et al.  p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905) , 2011, Clinical Cancer Research.

[20]  P. Guldberg,et al.  Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients , 2000, Breast Cancer Research.

[21]  D. Housman,et al.  p53 status and the efficacy of cancer therapy in vivo. , 1994, Science.

[22]  M. Schumacher,et al.  Prognostic and Predictive Effects of Immunohistochemical Factors in High-Risk Primary Breast Cancer Patients , 2006, Clinical Cancer Research.

[23]  L. Holmberg,et al.  Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  A. Børresen-Dale,et al.  TP53 and breast cancer , 2003, Human mutation.

[25]  L. Norton,et al.  p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Daidone,et al.  p53 expression, DNA content and cell proliferation in primary and synchronous metastatic lesions from ovarian surface epithelial-stromal tumours. , 1996, European journal of cancer.

[27]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  H. Altınyollar,et al.  Prognostic Factors Affecting Locoregional Recurrence in Patients with Stage IIIB Noninflammatory Breast Cancer , 2007, World Journal of Surgery.

[29]  L. Skoog,et al.  Proliferation rate, hormone receptor status and p53 expression in skeletal metastasis of breast carcinoma , 2004, Acta oncologica.

[30]  F. Akiyama,et al.  High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer , 2006, Breast cancer.

[31]  Y. Soini,et al.  A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients. , 2003, European journal of cancer.

[32]  J. Norman,et al.  Mutant p53 Drives Invasion by Promoting Integrin Recycling , 2009, Cell.

[33]  H. Clegg,et al.  Unlocking the Mdm2-p53 loop: Ubiquitin is the key , 2008, Cell cycle.